Last update: Nov. 9, 2014

Mometasone Topical Use

Very Low Risk for breastfeeding

Safe. Compatible.
Minimal risk for breastfeeding and infant.

At latest update, relevant information on excretion into breast milk was not found.

Topical use: because of a poor absorption through skin (0.4-0.7%), excretion into breast milk is unlikely. In addition, a high protein-binding capacity makes excretion even less likely.

When used for treatment of eczema or dermatitis of the nipple, it should be preferred a lower-potency steroid together with application just after a feed in order to let the medication has disappeared before the next meal.

Otherwise, wipe-out excess of cream by using a cotton gauze and avoid a continuous use for longer than one week.

Reportedly, one case of mineral-steroid toxicity occurred after a prolonged use on the nipple.

Do not use creams, gels and other locally applied products that contain paraffin (mineral oil) to prevent absorption by the infant.


We do not have alternatives for Mometasone Topical Use since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Mometasone Topical Use belongs to this group or family:


Main tradenames from several countries containing Mometasone Topical Use in its composition:

  • Elica
  • Elocom
  • Elocon™. Contains other elements than Mometasone Topical Use in its composition


Variable Value Unit
Oral Bioavail. 0,1 %
Molecular weight 427 daltons
Protein Binding 98 %
T1/2 5,8 hours


  1. Mometasona tópica Drug summary 2014 Abstract Full text (in our servers)
  2. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
  3. AEMPS Mometasona Tópica Ficha técnica 2007 Abstract Full text (in our servers)
  4. Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract
  5. Nice FJ, Snyder JL, Kotansky BC. Breastfeeding and over-the-counter medications. J Hum Lact. 2000 Nov;16(4):319-31. Review. Erratum in: J Hum Lact 2001 Feb;17(1):90. Abstract
  6. De Stefano P, Bongo IG, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. Helv Paediatr Acta. 1983 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by La Liga de la Leche de Euskadi

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM